Table 2.

The relationship between the FMD and clinical parameters in the type 2 diabetic patients with and without CHD.

Parameters	CHD (−)				CHD (+)
	Univariate		Multivariate		Univariate		Multivariate
	Regression coefficient	P	Regression coefficient	P	Regression coefficient	P	Regression coefficient	P
Age (years)	−0.036	0.01	−0.019	0.20	−0.015	0.44
Male (%)	−0.097	0.61			−0.018	0.94
Duration of diabetes mellitus (years)	−0.031	0.05			−0.030	0.14
Current smoker (%)	−0.146	0.47			−0.035	0.88
Body mass index (kg/m2)	−0.026	0.43			0.049	0.32
Obesity (%)	0.002	0.99			0.345	0.12
Medication
Insulin use (%)	−0.133	0.50			−0.408	0.08
RAS inhibitor use (%)	−0.335	0.07			−0.020	0.93
Statin use (%)	−0.231	0.23			−0.046	0.85
Xanthine oxidase inhibitors use (%)	−0.475	0.08			0.081	0.77
Systolic blood pressure (mmHg)	0.004	0.65			0.005	0.63
Diastolic blood pressure (mmHg)	0.016	0.20			0.007	0.69
Hypertension (%)	−0.133	0.55			−0.879	<0.01	−0.827	0.01
HbA1c (%)	0.143	0.09			0.016	0.90
LDL-cholesterol (mg/dL)	0.174	0.39			0.455	0.06
Hyper-LDL-cholesterolemia (%)	−0.127	0.50			0.005	0.98
HDL-cholesterol (mg/dL)	0.497	0.34			1.075	0.09
Hypo-HDL-cholesterolemia (%)	−0.008	0.97			−0.533	0.02	−0.501	0.02
Serum uric acid (mg/dL)	−0.004	0.03			−0.002	0.34
Hyperuricemia (%)	−0.007	0.97			0.034	0.88
Serum creatinine (mg/dL)	−0.002	0.26			−0.001	0.33
eGFR (mL/min/1.73 m2)	0.022	<0.01	0.016	0.02	0.015	0.06
Albuminuria (%)	−0.562	<0.01	−0.415	0.03	−0.449	0.07
ABI	1.124	0.52			0.928	0.56
baPWV (cm/s)	−0.001	0.20			−0.001	0.36
cIMT (mm)	−0.979	0.26			−1.497	0.11
Diabetic retinopathy (%)	−0.306	0.13			−0.027	0.42
Diabetic neuropathy (%)	−0.261	0.19			0.043	0.89

RAS inhibitors: renin-angiotensin system inhibitors (angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers).

Xanthine oxidase inhibitors: allopurinol or febuxostat.

Albuminuria: albuminuria stage A1 or A2.